abstract |
The present invention relates to compounds that specifically inhibit adenosine A1, A2a and A3 receptors, as well as to the use of these compounds in the treatment of diseases associated with A1, A2a and A3 adenosine receptors in subjects, comprising administering therapeutically effective amounts of the compounds to subjects. |